3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Multiple Myeloma
4
Lymphoma
4
Hodgkin Disease
4
Breast Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
3
Leukemia
3
Hematologic Neoplasms
3
Vomiting
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma in Situ
2
Burkitt Lymphoma
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Interventions
pembrolizumab
124
Cisplatin
27
lenvatinib
24
Carboplatin
24
Paclitaxel
19
Docetaxel
16
Fluorouracil
13
Capecitabine
11
Pemetrexed
10
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
olaparib
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Diphenhydramine
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts